Bavarian Nordic Investor Relations Material
Latest events
Q1 2025
Bavarian Nordic
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Bavarian Nordic
Access all reports
Bavarian Nordic is a clinical-stage biopharmaceutical company that develops and commercializes life-saving vaccines in the areas of cancer and infectious diseases. Its fast-growing portfolio today includes Aeras, an influenza vaccine that has been approved in the United States, Europe, and Canada, and the company is advancing a pipeline of novel, next generation vaccines designed to complement its portfolio. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.
Key slides for Bavarian Nordic
Q1 2025
Bavarian Nordic
Q1 2025
Bavarian Nordic
Latest articles
)
The Fifteenth Generation: A Conversation with Pietro Gussalli Beretta
An interview with Pietro Gussalli Beretta on how Beretta Holding blends 500 years of tradition with global growth, innovation, and long-term vision.
10 Jul 2025
)
Citadel: Relentless Optimization at Global Scale
From a Harvard dorm to global dominance, this is the story of how Ken Griffin created one of the best-performing hedge funds of all time.
4 Jul 2025
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
Ticker symbol
BAVA
Country
🇩🇰 Denmark